Azimuth Capital Investment Management LLC Raises Stock Position in CVS Health Corporation $CVS

Key Points

• Azimuth Capital increased its CVS Health stake by 25.1% in the second quarter, owning 135,609 shares worth approximately $14.0 million. Institutional investors and hedge funds collectively own 80.66% of the company.
• Analysts remain broadly positive, with 22 Buy ratings and two Holds, an overall “Moderate Buy” consensus, and an average price target of $106.83.
• CVS Health exceeded quarterly expectations, reporting $2.58 in EPS and $106.1 billion in revenue, while revenue grew 7.3% year over year. The company also maintains a quarterly dividend of $0.665 per share, yielding about 2.7% annually.

Azimuth Capital Investment Management LLC lifted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 25.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,609 shares of the pharmacy operator's stock after buying an additional 27,225 shares during the period. Azimuth Capital Investment Management LLC's holdings in CVS Health were worth $14,029,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd boosted its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the 4th quarter valued at approximately $26,000. Kilter Group LLC bought a new position in CVS Health during the second quarter worth $27,000. Sankala Group LLC bought a new position in shares of CVS Health in the 4th quarter worth about $28,000. Finally, Global Trust Asset Management LLC boosted its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on CVS. Argus increased their price objective on shares of CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a research note on Wednesday, August 19th. Barclays boosted their price objective on CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Piper Sandler reaffirmed an "overweight" rating on shares of CVS Health in a research report on Wednesday, August 26th. Sanford C. Bernstein raised their target price on CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Twenty-two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CVS Health has an average rating of "Moderate Buy" and a consensus target price of $106.83.

CVS Health Price Performance

NYSE:CVS opened at $96.80 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The business's 50-day moving average price is $100.79 and its 200 day moving average price is $90.14. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The firm has a market cap of $123.80 billion, a P/E ratio of 25.61, a PEG ratio of 0.94 and a beta of 0.59.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. During the same period in the previous year, the firm posted $1.81 EPS. The company's quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. CVS Health's dividend payout ratio (DPR) is 70.37%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.